Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher, striking a $180 million sale that reflects the high market demand for a speedy FDA review.
Rocket Pharmaceuticals has offloaded its lucrative FDA rare pediatric disease priority review voucher, striking a $180 million sale that reflects the high market demand for a speedy FDA review.
Rising Stars: A strategic marketing lead at CDMO Axplora, Arsalan Khan is also a chemical and pharmaceutical engineer, a published author and an avid tennis player.
Despite being widely used by gym-goers, even one popular supplement has its limitations, according to new research.
Sen. Adam Schiff (D-Calif.) said Sunday that the Department of Justice (DOJ) sought another grand jury indictment of James Comey because acting Attorney General Todd Blanche …